TITLE:
Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU

CONDITION:
Invasive Fungal Infections

INTERVENTION:
Micafungin

SUMMARY:

      The purpose of this study is to determine the efficacy and safety of intravenous micafungin
      versus placebo as prophylactic therapy for invasive fungal infections in patients in the
      intensive care unit considered to be at high risk.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 16 Years to N/A
Criteria:

        Inclusion Criteria

          -  Meets entry criteria for high risk

        Exclusion Criteria

          -  Evidence of active invasive fungal infection

          -  Received more than one dose of systemic antifungal agent within 72 hours prior to
             first dose of study drug

          -  Known to be HIV positive who have CD4 count less than 500 cells/mm3

          -  Has life-expectancy of less than 72 hours or moribund
      
